Optimi Health Corp. Common Shares (OPTH) - Total Liabilities
Based on the latest financial reports, Optimi Health Corp. Common Shares (OPTH) has total liabilities worth $5.79 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check OPTH cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Optimi Health Corp. Common Shares - Total Liabilities Trend (2020–2025)
This chart illustrates how Optimi Health Corp. Common Shares's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Optimi Health Corp. Common Shares total assets.
Optimi Health Corp. Common Shares Competitors by Total Liabilities
The table below lists competitors of Optimi Health Corp. Common Shares ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Xali Gold Corp
V:XGC
|
Canada | CA$14.28 Million |
|
Korean Drug Co. Ltd
KQ:014570
|
Korea | ₩20.08 Billion |
|
SIAV S.P.A.
F:F4U
|
Germany | €40.55 Million |
|
eMnet Inc
KQ:123570
|
Korea | ₩33.36 Billion |
|
BIONXT SOLUTIONS INC.
F:BXT
|
Germany | €7.65 Million |
|
Hunyvers SA
PA:ALHUN
|
France | €75.34 Million |
|
Aetherium Acquisition Corp
NASDAQ:GMFI
|
USA | $10.13 Million |
|
Lotus Eye Hospital and Institute Limited
NSE:LOTUSEYE
|
India | Rs108.97 Million |
Liability Composition Analysis (2020–2025)
This chart breaks down Optimi Health Corp. Common Shares's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Optimi Health Corp. Common Shares balance sheet independence to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.73 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.47 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.32 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Optimi Health Corp. Common Shares's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Optimi Health Corp. Common Shares (2020–2025)
The table below shows the annual total liabilities of Optimi Health Corp. Common Shares from 2020 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-09-30 | $8.65 Million | +73.94% |
| 2024-09-30 | $4.98 Million | +51.65% |
| 2023-09-30 | $3.28 Million | +311.30% |
| 2022-09-30 | $797.66K | -66.70% |
| 2021-09-30 | $2.40 Million | +171.38% |
| 2020-09-30 | $882.66K | -- |
About Optimi Health Corp. Common Shares
Optimi Health Corp. operates as a pharmaceutical and nutraceutical drug manufacturing company in Canada. The company manufactures controlled substances including finished MDMA and psilocybin drug products, supplying them directly to authorized clinics, pharmacies, clinical trials, and partners. The company produces and supplies MDMA, natural psilocybin, psilocin, other psychedelic substances, and… Read more